Rice University has launched the Institute of Health Resilience and Innovation (IHRI), a pioneering research initiative dedicated to understanding the lifetime impacts of health stressors and ...

United Therapeutics (UTHR) announced that ten posters and presentations across its commercial and development portfolio will be presented at ...

Learn more about whether Blueprint Medicines Corporation or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Carisma Therapeutics (NASDAQ:CARM – Get Free Report) had its price objective cut by equities researchers at D. Boral Capital from $12.00 to $1.00 in a report issued on Tuesday,Benzinga reports. The ...

Amit Gupta, MD, discussed a new collaboration between University Hospitals Cleveland Medical Center and Qure.ai that aims to ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

D Molecular Therapeutics, Inc.’s FDMT share price has dipped by 10.90%, which has investors questioning if this is right time to buy.

Volatility and Risk Finch Therapeutics Group has a beta of 1.21, indicating that its share price is 21% more volatile than ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...